Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV randomized double-blind active-controlled study of An'erlaifu influenza split vaccine in pregnant women
CTR20263477Phase 4Active
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of An'erlaifu in influenza (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion rate of hemagglutination inhibition antibodies by vaccine strain and Adverse reaction rate. Started Sep 2026; status: active.
02
Drugs
An'erlaifu
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20263477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263477.